Bajaj Healthcare Ltd, incorporated in 1993, specializes in the production of Active Pharmaceutical Ingredients (APIs) and pharmaceutical formulations with a strong global footprint. The company supplies to both advanced and emerging markets, ensuring regulatory compliance and product innovation.
Q2 FY26 Earnings Summary
- Consolidated revenue grew 11.28% year on year to ₹148 crore, up from ₹133 crore.\
- Total expenses increased 8.06% to ₹134 crore, compared to ₹124 crore last year.
- Consolidated net profit rose 22.22% to ₹11 crore, versus ₹9 crore in Q2 FY25.
- Earnings per share (EPS) was ₹3.52, up 17.33% from ₹3.00 a year ago.
Operational and Business Highlights
- Q2 FY26 saw strong growth in API exports (up 67% YoY), offsetting a slight decline in domestic API performance.
- Formulation business remained stable with ongoing resilience despite a minor revenue dip.
- Margin expansion was driven by higher export volumes and operational efficiencies. Gross margin improved sequentially by 462 basis points to 50.8%. EBITDA margin expanded to 19.1%.icicidirect+1
- Bajaj Healthcare received key regulatory nods: phase III clinical trials for Suvorexant and Cenobamate tablets, as well as new CEP and DMF filings in regulated markets.
Financial Strength and Outlook
- The company maintained a solid balance sheet, enhanced regulatory preparedness, and strategic investments in R&D.
- Management remains focused on expanding product registrations and targeting high-value therapeutic areas for long-term growth.
- Bajaj Healthcare continues to leverage its global presence, compliance, and innovation to sustain earnings growth through FY26 and beyond.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.